| 1 |
NCT02335112 |
Recruiting |
Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms |
|
- Procedure: Irreversible electroporation (IRE)
- Device: NanoKnife
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse events
- Percentage of lesions that show no sign of recurrence 12 months after IRE
- Voltage (A minimum and maximum range of voltage for safe and effective IRE)
- (and 2 more...)
|
15 |
All |
Child, Adult, Older Adult |
NCT02335112 |
ZhangZhikai-IRE-02 |
IRE |
January 2015 |
January 2017 |
January 2020 |
January 9, 2015 |
March 29, 2016 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 2 |
NCT03047174 |
Recruiting |
Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer |
|
- Other: Mepitel® Film
- Other: Standard Care
|
Interventional
|
Not Applicable |
- University of Schleswig-Holstein
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Superiority in prevention of grade ≥2 radiation dermatitis
- Time to grade 2 radiation dermatitis until 50 Gy of radiotherapy
- Rate of patients experiencing grade ≥2 radiation dermatitis during radio(chemo)therapy
- (and 4 more...)
|
168 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03047174 |
RAREST-01 |
RAREST-01 |
May 9, 2017 |
April 2019 |
August 2019 |
February 8, 2017 |
July 11, 2017 |
|
- Department of Radiotherapy (Radiooncology), Christian-Albrechts-Universität zu Kiel and University Medical Center Schleswig-Holstein Campus Kiel
Kiel, Schleswig-Holstein, Germany - Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein
Lubeck, Germany
|
|
| 3 |
NCT02989259 |
Recruiting |
Apatinib for Advanced Non-squamous Head and Neck Cancer |
|
|
Interventional
|
Phase 2 |
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression-free survival
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02989259 |
CH-H&N-008-1 |
|
December 2016 |
December 2018 |
December 2021 |
December 12, 2016 |
December 13, 2016 |
|
- Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)
Beijing, Beijing, China
|
|
| 4 |
NCT02836769 |
Recruiting |
Development and Evaluation of Rehabilitation Consult for Survivors of Head and Neck Cancer |
|
- Behavioral: Rehabilitation Consult (RC)
|
Interventional
|
Not Applicable |
- Sunnybrook Health Sciences Centre
- Princess Margaret Hospital, Canada
- Toronto General Hospital
- University Health Network, Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Functional Assessment of Cancer Therapy - Head and Neck (FACT - H&N)
- Change in Medical Outcome Short Form (36) Health Survey - (SF-36)
- Change in goal performance, satisfaction, and self-efficacy
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT02836769 |
246-2013 |
HNC-RC |
January 2016 |
December 2017 |
May 2018 |
July 19, 2016 |
April 27, 2017 |
|
- Sunnybrook Health Sciences Centre, Odette Cancer Centre
Toronto, Ontario, Canada - University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
|
|
| 5 |
NCT02943252 |
Recruiting |
The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer |
|
|
Interventional
|
Phase 2 |
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression-free survival
- Overall survival
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02943252 |
CH-H&N-008 |
|
October 2016 |
October 2019 |
October 2021 |
October 24, 2016 |
October 24, 2016 |
|
- Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)
Beijing, Beijing, China
|
|
| 6 |
NCT03546322 |
Not yet recruiting
New |
Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers |
|
|
Observational
|
|
- University of California, San Francisco
- Agency for Healthcare Research and Quality (AHRQ)
|
Other / U.S. Fed |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Workup and Treatment Planning - Primary Outcome
- Treatment - Primary Outcome
- Workup and Treatment Planning - Secondary Outcome #1
- (and 4 more...)
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT03546322 |
P30HS023558-1
P30HS023558 |
|
June 2018 |
May 2019 |
May 2023 |
June 5, 2018 |
June 5, 2018 |
|
|
|
| 7 |
NCT03443258 |
Not yet recruiting |
Needs Assessment Tool Integrated in Clinical Practice of Head and Neck Cancer Rehabilitation |
|
- Other: Needs assesment tool integrated in nursing consultation.
|
Interventional
|
Not Applicable |
- Rigshospitalet, Denmark
- Novo Nordisk A/S
- Danish Nurses Organisation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in Health Related Quality of Life, from baseline to 9, 21 and until 67 days post surgery
- Change in Symptom Burden from baseline to 2, 14 and 60 days post-surgery
|
128 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03443258 |
05781 |
NEAT |
April 2018 |
March 2019 |
May 2019 |
February 23, 2018 |
February 23, 2018 |
|
- Dept. Of Otorhinolaryngology, Head and Neck Surgery and Audiology
Copenhagen, Denmark
|
|
| 8 |
NCT03114202 |
Recruiting |
Effects of Nutritional Counseling on Nutritional Status and Quality of Life of Head and Neck Cancer Patients |
|
- Other: intensive nutritional counseling
- Other: Standard care
|
Interventional
|
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in weight
- Change in nutritional status
- Change in quality of life
- (and 6 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT03114202 |
1.954.066 |
|
April 18, 2017 |
August 6, 2018 |
October 1, 2018 |
April 14, 2017 |
July 19, 2017 |
|
- Centro de Oncologia da Santa Casa Nossa Senhora do Perpétuo Socorro
Alfenas, Minas Gerais, Brazil - Fundação Hospitalar do Município de Varginha - Hospital Bom Pastor
Varginha, Minas Gerais, Brazil
|
|
| 9 |
NCT00200486 |
Recruiting |
Molecular and Genomic Profiling of Head and Neck Tumors |
|
|
Observational
|
|
- Montefiore Medical Center
- National Institutes of Health (NIH)
- National Institute of Dental and Craniofacial Research (NIDCR)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- correlation of treatment response and prognosis (time to recurrence and survival) with genetic expression profile
- identify a series of diagnostic markers for head and neck tumors and study the mechanism of action of these proteins
|
400 |
All |
Child, Adult, Older Adult |
NCT00200486 |
02-05-127E
NIH-R21-CA104402
6R21DE023941-03 |
|
May 2002 |
May 2020 |
May 1, 2020 |
September 20, 2005 |
March 20, 2018 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 10 |
NCT02485470 |
Recruiting |
Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy |
|
|
Interventional
|
Phase 2 |
- University of Michigan Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Mean change in 6 minute walk distance (6MWD)
|
180 |
All |
40 Years and older (Adult, Older Adult) |
NCT02485470 |
UMCC 2015.073
HUM00100889 |
|
February 2016 |
February 2020 |
February 2021 |
June 30, 2015 |
September 18, 2017 |
|
- The University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
|
|
| 11 |
NCT02421458 |
Recruiting |
Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer |
|
- Radiation: 6 x 6 Gy
- Radiation: 16 x 3.125 Gy
|
Interventional
|
Not Applicable |
- The Netherlands Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- time to loco-regional progression
- impact of both radiation schemes on QoL
- overall survival rates
- (and 4 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02421458 |
M15CRH |
COOPERATION |
November 2015 |
November 2019 |
November 2021 |
April 20, 2015 |
February 14, 2018 |
|
- Medisch Spectrum Twente
Enschede, Overijssel, Netherlands - Leids Universitair Medisch Centrum
Leiden, Zuid Holland, Netherlands - Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands - (and 8 more...)
|
|
| 12 |
NCT03175289 |
Recruiting |
Expiratory Muscle Strength Training in Improving Bulbar Function and Quality of Life in Patients With Head and Neck Cancer |
- Malignant Head and Neck Neoplasm
|
- Other: Best Practice
- Other: Educational Intervention
- Other: Exercise Intervention
- (and 3 more...)
|
Interventional
|
Not Applicable |
- Ohio State University Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Airway safety during swallowing assessed using the Penetration-Aspiration Scale
- Eating Assessment Tool-10
- Expiratory flow assessed using portable digital peak flow meter
- (and 7 more...)
|
70 |
All |
19 Years to 78 Years (Adult, Older Adult) |
NCT03175289 |
OSU-16023
NCI-2017-00848 |
|
September 29, 2016 |
June 2019 |
June 2019 |
June 5, 2017 |
December 14, 2017 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
|
| 13 |
NCT03019003 |
Recruiting |
Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients |
|
- Drug: Azacitidine
- Drug: Durvalumab
- Drug: Tremelimumab
|
Interventional
|
Phase 1
Phase 2 |
- Massachusetts General Hospital
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: Biologically Effective Dose (BED) of azacitidine
- Phase II: Progression free survival (PFS)
- Phase I: Number of participants with treatment-related adverse events
- (and 2 more...)
|
59 |
All |
18 Years and older (Adult, Older Adult) |
NCT03019003 |
16-425 |
|
March 20, 2017 |
July 2020 |
July 2024 |
January 12, 2017 |
June 12, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 14 |
NCT02869399 |
Recruiting |
Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention |
|
- Dietary Supplement: dietary intervention in addition to standard recommendations
|
Interventional
|
Phase 2 |
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction in the incidence of tumor recurrence and second primaries
- Identification of saliva and plasma miRNAs and evaluation of their change in the 2 arms of treatment
- Change in inflammatory cytokine profile during the course of dietary intervention
- (and 4 more...)
|
350 |
All |
18 Years and older (Adult, Older Adult) |
NCT02869399 |
INT 18/15 |
DietINT |
November 2015 |
November 2018 |
November 2018 |
August 17, 2016 |
August 23, 2016 |
|
- Medical University of Vienna
Vienna, Austria - Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde
Leipzig, Germany - Fondazione IRCCS Istituto Nazionale Tumori
Milan, Lombardy, Italy - (and 3 more...)
|
|
| 15 |
NCT02549742 |
Recruiting |
Electrochemotherapy on Head and Neck Cancer |
|
- Procedure: Electrochemotherapy
- Device: Cliniporator
- Drug: Bleomycin
|
Interventional
|
Phase 2 |
- Rigshospitalet, Denmark
- Copenhagen University Hospital at Herlev
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumour response from PET/CT scans (Positron Emission Tomography - Computed Tomography)
- Tumour response from MRI scans (Magnetic resonance imaging)
- Tumour response from tissue samples
- (and 3 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02549742 |
HH1222 |
|
February 2014 |
September 2019 |
September 2019 |
September 15, 2015 |
January 18, 2017 |
|
- Department of Otorhinolaryngology, Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark
|
|
| 16 |
NCT03051269 |
Recruiting |
Calcium Electroporation for Head and Neck Cancer |
|
- Drug: Calcium chloride
- Device: Electroporation
|
Interventional
|
Phase 1 |
- Rigshospitalet, Denmark
- Herlev Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Treatment-Emergent Adverse Events [Safety and Tolerability]
- Tumour response
- Comparing calcium electroporation to electrochemotherapy
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT03051269 |
HC1511 |
|
May 2016 |
December 2018 |
February 2019 |
February 13, 2017 |
February 13, 2017 |
|
- Department of Otorhinolaryngology, Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark
|
|
| 17 |
NCT03051906 |
Not yet recruiting |
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer |
|
- Biological: Durvalumab
- Biological: Cetuximab
- Radiation: Intensity modulated radiation therapy (IMRT)
|
Interventional
|
Phase 1
Phase 2 |
- Azienda Ospedaliero-Universitaria Careggi
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the efficacy of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
- To assess the number of participants with treatment-related adverse events according to CTCAE v.4
- To assess the tolerability of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
- (and 2 more...)
|
69 |
All |
18 Years and older (Adult, Older Adult) |
NCT03051906 |
DUCRO-HN
2016-004668-20 |
DUCRO-HN |
January 2018 |
January 2022 |
January 2025 |
February 14, 2017 |
November 22, 2017 |
|
|
|
| 18 |
NCT02900963 |
Recruiting |
Nutritional Status Assessment in Head and Neck Cancer Patients Receiving Radiotherapy or Chemo-radiotherapy |
|
- Other: weekly assessment of patient's weight
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- weight
- Nutritional status determination
- Inflammatory status
- BMI calculation
|
280 |
All |
18 Years and older (Adult, Older Adult) |
NCT02900963 |
CHB 13.04 |
NUTRINECK |
April 2014 |
August 2018 |
September 2019 |
September 15, 2016 |
July 21, 2017 |
|
- Centre Henri Becquerel
Rouen, France
|
|
| 19 |
NCT03106090 |
Recruiting |
Studying Survivorship Care Plans in Head and Neck Cancer |
|
- Other: educational materials
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Head and Neck Cancer Survivor Knowledge
- Change in Head and Neck Cancer Survivor Knowledge
- Distress in head and neck cancer survivors
- (and 11 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT03106090 |
Pro00079937 |
|
April 19, 2017 |
March 30, 2019 |
March 30, 2019 |
April 10, 2017 |
April 18, 2018 |
|
- Duke Health, Duke Cancer Center
Durham, North Carolina, United States
|
|
| 20 |
NCT02906800 |
Recruiting |
Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients |
|
|
Interventional
|
Phase 1
Phase 2 |
- Assistance Publique - Hôpitaux de Paris
- Cancer Research and Personalized Medicine (Carpem)
- Laboratoire d’excellence en immuno-oncologie (Labex)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Appearance of the grade 3 or 4 (Adverse Events graded by NCI CTC version 4.0) clinical or biological toxicity of the combination of digoxin to cisplatin-based chemotherapy during the study
- Clinical response after chemotherapy by fibroscopy (tumor seize)
- Radiological response after chemotherapy
- (and 5 more...)
|
15 |
All |
19 Years to 69 Years (Adult, Older Adult) |
NCT02906800 |
P150401
2015-003076-78 |
DIGHANC |
January 2017 |
May 2019 |
May 2019 |
September 20, 2016 |
October 19, 2017 |
|
- Hopital Europeen Georges Pompidou
Paris, Île-de-France, France
|
|
| 21 |
NCT03531190 |
Not yet recruiting |
Pre- and Postoperative Nutrition in Head and Neck Cancer Patients |
|
- Dietary Supplement: Nutritional supplement (Protein + MIX)
- Dietary Supplement: Nutritional supplement (Protein)
|
Interventional
|
Not Applicable |
- University of Copenhagen
- Rigshospitalet, Denmark
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- POSAS-scale (The Patient and Observer Scar Assessment Scale v2.0 / EN)
- Appearance of the scar (scale)
- Ultrasound scanning
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03531190 |
H-17040654 |
|
May 10, 2018 |
November 30, 2018 |
November 30, 2018 |
May 21, 2018 |
May 21, 2018 |
|
|
|
| 22 |
NCT02409485 |
Recruiting |
Improving Self-Management in Head and Neck Cancer |
|
- Behavioral: Couples Skill-Training (CST)
|
Interventional
|
Not Applicable |
- Baylor College of Medicine
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility of the CST intervention as assessed by recruitment and retention rates
- Acceptability of the CST intervention as assessed by the program evaluation questionnaire
- PROMIS short form anxiety and depression
- (and 4 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02409485 |
GCO 12-1641
R21CA178478
H-48778 |
|
November 2014 |
July 2018 |
July 2018 |
April 6, 2015 |
August 25, 2017 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
|
| 23 |
NCT02965001 |
Recruiting |
Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer |
|
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Freedom from any failure
- Overall Survival
- Disease free survival
- (and 2 more...)
|
104 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02965001 |
366_16 |
|
November 2016 |
December 2019 |
December 2019 |
November 16, 2016 |
April 11, 2018 |
|
- Departmen of Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark
|
|
| 24 |
NCT02489084 |
Recruiting |
Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP) |
|
|
Observational
|
|
- University Medical Center Groningen
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in acute toxicity
- Change in late toxicity
- Change in patient-rated symptoms
- Change in patient-rated Quality-of-Life
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02489084 |
RT2011-03 |
HANS |
September 2013 |
December 2020 |
December 2020 |
July 2, 2015 |
January 5, 2018 |
|
- University Medical Center Groningen
Groningen, Netherlands
|
|
| 25 |
NCT02017288 |
Recruiting |
Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan |
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Taiwan University
- Academia Sinica, Taiwan
- (and 2 more...)
|
NIH / Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Progression to dysplasia/cancer in participants with oral precursors.
|
5000 |
All |
21 Years to 100 Years (Adult, Older Adult) |
NCT02017288 |
999914018
14-C-N018 |
|
December 19, 2013 |
November 30, 2025 |
November 30, 2025 |
December 20, 2013 |
June 13, 2018 |
|
- Chang Gung Memorial Hospital
Taipei, China - China Medical University Hospital
Taichung, Taiwan - National Taiwan University
Taipei, Taiwan - Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan
|
|
| 26 |
NCT02546895 |
Recruiting |
Prospective Registration of Head and Neck Cancer |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression-free survival
- Quality of life
- Identification of biomarkers of clinical significance (prognostic)
- (and 5 more...)
|
2000 |
All |
19 Years and older (Adult, Older Adult) |
NCT02546895 |
2015-06-132 |
|
September 2015 |
December 2022 |
December 2022 |
September 11, 2015 |
April 18, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 27 |
NCT02900911 |
Recruiting |
Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy |
|
- Other: Early rehabilitation
- Other: Late rehabilitation
|
Interventional
|
Not Applicable |
- Parc de Salut Mar
- Asociación Española contra el Cáncer
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in dysphagia severity at three months post radiotherapy
- Change in quality of life at three months post radiotherapy
- Change in dysphagia security signs at three months post radiotherapy
- Change in lingual Force at three months post radiotherapy
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT02900911 |
2014/5707/l |
ReDyOR |
May 2016 |
December 2018 |
June 2019 |
September 14, 2016 |
September 21, 2017 |
|
- Hospital de l'Esperança
Barcelona, Spain
|
|
| 28 |
NCT00230308 |
Recruiting |
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer |
|
|
Observational
|
|
|
Other |
- Time Perspective: Prospective
|
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT00230308 |
ENT0008
76537
11402 |
|
April 2002 |
December 2019 |
December 2024 |
September 30, 2005 |
November 10, 2016 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
|
| 29 |
NCT01504815 |
Recruiting |
Adaptive Radiation Treatment for Head and Neck Cancer |
|
- Drug: cisplatinum
- Radiation: Conventional radiotherapy
- Radiation: Adaptive radiotherapy
|
Interventional
|
Phase 3 |
- The Netherlands Cancer Institute
- Karolinska Institutet
- Maastricht Radiation Oncology
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- locoregional recurrence-free survival
- number of patients with grade 3 toxicity or more
- Quality of Life assessment
- (and 3 more...)
|
268 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01504815 |
M11ART |
ARTFORCE |
March 2012 |
April 2019 |
September 2021 |
January 5, 2012 |
September 28, 2017 |
|
- Gustave Roussy Cancer Institute
Villejuif, France - Netherlands Cancer Institute
Amsterdam, Netherlands - Universitair Medisch Centrum Groningen
Groningen, Netherlands - (and 6 more...)
|
|
| 30 |
NCT02918955 |
Recruiting |
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection |
|
- Procedure: up-front neck dissection
- Radiation: radiotherapy
- Drug: Chemotherapy (Cisplatin)
- Procedure: Early Salvage Neck Dissection in case of less than cCR (Arm A only)
|
Interventional
|
Phase 3 |
- University Hospital Inselspital, Berne
- University of Bern
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with acute & subacute toxicity based on CTCAE scoring system v4.03
- Number of patients with late Toxicity based on CTCAE scoring system v4.03
- Change from baseline quality of life(QoL)using EORTC QLQ-C30 v3&EORTC QLQ-H&N43 modules(Health related QoL specific for Head&Neck ca.)scores at end of RT, 3,12&24 months after RT.Swallowing (H&N43:4-item scale)3 months after RT is the primary QoL domain
- (and 6 more...)
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT02918955 |
BE 00733/16 |
UPFRONT-NECK |
October 2016 |
March 2020 |
June 2022 |
September 29, 2016 |
May 4, 2018 |
|
- Inselspital Bern
Bern, Switzerland - Genève University Hospital
Geneva, Switzerland
|
|
| 31 |
NCT03491176 |
Recruiting |
Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer |
|
- Procedure: MRI
- Procedure: Blood Draw
- Behavioral: Questionnaires
|
Interventional
|
Not Applicable |
- M.D. Anderson Cancer Center
- Radiological Society of North America
- The Royal Australian and New Zealand College of Radiologists
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Tumor Growth Velocity (TGV)
- Tumor Kinetics (TK)
- Change in Blood Biomarkers of Mucosal Head and Neck Cancers During Radiation Therapy (RT)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03491176 |
PA16-1041
RF1701 |
|
May 18, 2017 |
May 2020 |
May 2021 |
April 9, 2018 |
April 9, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 32 |
NCT02385929 |
Recruiting |
Pre-habilitation of Patients With Head and Neck Cancer |
|
- Behavioral: Swallowing therapy & resistance training
|
Interventional
|
Not Applicable |
- Irene Wessel
- Danish Cancer Society
- Danish Association of Occupational Therapist
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Swallowing function measured by penetration aspiration scale (PAS) during a Fiber Endoscopic Evaluation of Swallowing (FEES).
- Level of fatigue by the EORCT QLQ-C30 3-point fatigue subscale.
- Maximal Interincisal Distance (MID) by Therabite Range of Motion (ROM) scale
- (and 10 more...)
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT02385929 |
H-2-2014-074
R108-A6969-14-S31 |
SYNK |
May 11, 2015 |
October 2019 |
October 2019 |
March 11, 2015 |
April 11, 2018 |
|
- Næstved Sygehus
Næstved, Region Zealand, Denmark - Rigshospitalet
Copenhagen, Denmark
|
|
| 33 |
NCT03164460 |
Recruiting |
Reirradiation for Small Inoperable Head and Neck Tumors |
|
- Radiation: SBRT
- Radiation: IMRT/IMPT
- Behavioral: Questionnaires
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Grade 3 or Higher CTCAE Toxicity Between Stereotactic Ablative Radiotherapy (SBRT) versus Intensity Modulated Radiation Therapy/Intensity Modulated Proton Therapy (IMRT/IMPT)
- Local Control Between IMRT/IMPT and SBRT
- Locoregional Failure-Free Survival (LFFS) Between IMRT/IMPT and SBRT
- Compare Patient Reported Outcome (PRO) Measures of Symptoms using MD Anderson Symptom Inventory (MDASI)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03164460 |
2016-1065 |
|
May 22, 2017 |
May 2022 |
May 2023 |
May 23, 2017 |
February 19, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 34 |
NCT02429037 |
Not yet recruiting |
P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer |
- Advanced Head and Neck Cancer
|
- Drug: rAd-p53
- Radiation: radiation
- Drug: Cisplatin
|
Interventional
|
Phase 2 |
- Shenzhen SiBiono GeneTech Co.,Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival
- Adverse events
- overall survival
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02429037 |
rAd-p53-J1002 |
|
May 2015 |
December 2018 |
December 2018 |
April 29, 2015 |
April 29, 2015 |
|
- Jiangsu cancer hospital
Nanjing, Jiangsu, China
|
|
| 35 |
NCT02059668 |
Recruiting |
Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio) |
|
- Biological: Biomarker analyses head & neck cancer tissue, blood specimen
|
Observational
|
|
- Technische Universität Dresden
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- local recurrence free survival
- disease-free survival
- metastases-free survival
- overall survival
|
550 |
All |
18 Years and older (Adult, Older Adult) |
NCT02059668 |
STR- HNprädBio-2013 |
HNprädBio |
March 2014 |
September 2021 |
September 2023 |
February 11, 2014 |
November 7, 2017 |
|
- Prof. Anca-Ligia Grosu
Freiburg, Baden-Wuerttemberg, Germany - Prof. Jürgen Debus
Heidelberg, Baden-Wuerttemberg, Germany - Prof. Daniel Zips
Tübingen, Baden-Wuerttemberg, Germany - (and 7 more...)
|
|
| 36 |
NCT02975739 |
Recruiting |
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors |
- Radioisotopes
- Head and Neck Neoplasms
|
- Device: Holmium-166 (poly L lactic acid) microspheres
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Total amount of activity leakage (in percentage) in the oral cavity rinsing fluid.
- Occurrence of (serious) adverse events
- The biodistribution of Holmium-166 microspheres after intra-tumoural injection
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02975739 |
NL54535.041.15 |
HIT |
September 2016 |
December 2017 |
December 2017 |
November 29, 2016 |
November 29, 2016 |
|
- University Medical Center Utrecht
Utrecht, Netherlands
|
|
| 37 |
NCT01818323 |
Recruiting |
Phase I Trial: T4 Immunotherapy of Head and Neck Cancer |
|
- Other: Intra-tumoral T4 immunotherapy
|
Interventional
|
Phase 1 |
- King's College London
- Guy's and St Thomas' NHS Foundation Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Dose limiting toxicities for T4 immunotherapy in SCCHN and determine a safe and feasible recommended dose for phase II testing of intra-tumoral T4 immunotherapy.
- To investigate serum cytokine levels after administration of T4 immunotherapy
- To investigate persistence of T4+ T-cells at the site of administration and in the peripheral circulation
- (and 4 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01818323 |
2012-001654-25 |
|
June 2015 |
June 2019 |
December 2019 |
March 26, 2013 |
August 18, 2017 |
|
- Clinical Research Facility, Guy's Hospital
London, United Kingdom
|
|
| 38 |
NCT03532737 |
Not yet recruiting |
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer |
- Locally Advanced Head and Neck Cancer
|
|
Interventional
|
Phase 2 |
- Kuwait Cancer Control Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT)
- Response Rate
- Locoregional control rates
- (and 2 more...)
|
50 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03532737 |
HNIT 01 |
|
October 1, 2018 |
September 30, 2021 |
October 31, 2022 |
May 22, 2018 |
May 22, 2018 |
|
- Kuwait Cancer Control Center
Kuwait, Kuwait
|
|
| 39 |
NCT03297957 |
Recruiting |
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Head and Neck Cancer |
- Head and Neck Cancer
- Cancer of the Head and Neck
|
- Drug: IC-GREEN
- Device: Hands-free goggle system
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure
- Determine if there is contrast between SLN and surrounding tissues using the novel fluorescence imaging device
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03297957 |
201708068 |
|
September 14, 2017 |
September 30, 2018 |
September 30, 2018 |
September 29, 2017 |
October 6, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 40 |
NCT03217188 |
Recruiting |
Proton Re-Irradiation for Recurrent Head and Neck Cancer |
|
- Radiation: conventionally fractionated full dose re-irradiation
- Radiation: hypofractionated palliative re-irradiation
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- locoregional recurrence-free
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT03217188 |
17-300 |
|
July 10, 2017 |
July 2020 |
July 2020 |
July 14, 2017 |
October 26, 2017 |
|
- Memoral Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States - Memoral Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Commack
Commack, New York, United States - (and 3 more...)
|
|
| 41 |
NCT03431363 |
Not yet recruiting |
Medical Cannabis During Chemoradiation for Head and Neck Cancer |
|
|
Observational
|
|
- Albert Einstein College of Medicine, Inc.
|
Other |
|
- Patients' adherence to registering for medically certified cannabis
- Patients' adherence to procuring medically certified cannabis
- Length of time for patients to obtain medically certified cannabis
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03431363 |
2017-8493 |
|
May 2018 |
February 2020 |
June 2020 |
February 13, 2018 |
April 19, 2018 |
|
|
|
| 42 |
NCT03065634 |
Recruiting |
Return to Work and Living Healthy After Head and Neck Cancer |
|
- Behavioral: Return to work and living healthy after head and neck cancer
- Behavioral: socio-legal counseling
|
Interventional
|
Not Applicable |
- University of Leipzig
- Universitätsklinikum Leipzig
- Jena University Hospital
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Work ability
- Pattern of work-related coping behaviour
- Quality of Life
- (and 4 more...)
|
144 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03065634 |
93000-133 |
RELIANCE |
January 1, 2017 |
December 31, 2018 |
December 31, 2019 |
February 28, 2017 |
February 28, 2017 |
|
- University Medical Center Leipzig
Leipzig, Saxony, Germany
|
|
| 43 |
NCT02555644 |
Recruiting |
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer |
|
- Drug: Prexasertib
- Drug: Cisplatin
- Drug: Cetuximab
- Radiation: Intensity Modulated Radiation Therapy
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part A: Maximum Tolerated Dose of Prexasertib in Combination with Cisplatin and Radiation Therapy
- Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab and Radiation Therapy
- Pharmacokinetics (PK): Maximum Concentration of Prexasertib, Cisplatin and Cetuximab
- (and 2 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT02555644 |
16016
I4D-MC-JTJI
2015-001215-12 |
|
February 2016 |
October 2018 |
October 2018 |
September 21, 2015 |
October 4, 2017 |
|
- University of Alabama-Birmingham
Birmingham, Alabama, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Lyon, France - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Villejuif, France
|
|
| 44 |
NCT03317730 |
Recruiting |
Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer |
- Locally Advanced Head and Neck Cancer
|
|
Interventional
|
Early Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of Xtampza ER during radiotherapy (RT) for locally advanced head and neck cancer (LAHNC).
- Determine Pain Control (at time of enrollment)
- Determine Pain Control (weekly during RT)
- (and 3 more...)
|
50 |
All |
19 Years and older (Adult, Older Adult) |
NCT03317730 |
IRB-300000574 |
RAD 1702 |
May 1, 2018 |
October 2019 |
December 2019 |
October 23, 2017 |
May 22, 2018 |
|
- Hazelrig-Salter Radiation Oncology Center
Birmingham, Alabama, United States
|
|
| 45 |
NCT03506451 |
Not yet recruiting |
PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study |
|
- Other: Demographics questionnaires and the FACT HN questionnaire
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Financial toxicity, as measured by out of pocket (OOP) costs for a definitive course of treatment for HNC
- Financial toxicity, as measured by change in Comprehensive Score for financial Toxicity (COST)
- Change in symptom burden, as measured by Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) score
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03506451 |
Pro00092590 |
PaRTNer |
June 2018 |
June 2021 |
June 2025 |
April 24, 2018 |
April 24, 2018 |
|
|
|
| 46 |
NCT03402737 |
Recruiting |
SBRT + Cyclophosphamide for Inoperable, Recurrent H&N |
|
- Radiation: Stereotactic body radiotherapy
|
Interventional
|
Not Applicable |
- University Hospital, Ghent
|
Other |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dose
- symptom palliation - pain
- symptom palliation - dysphagia
- (and 9 more...)
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03402737 |
EC/2017/0636
2017-000133-31 |
|
July 31, 2017 |
December 2018 |
December 2019 |
January 18, 2018 |
January 19, 2018 |
|
- Radiotherapy department, University Hospital Ghent
Ghent, Oost-Vlaanderen, Belgium - UZ Leuven
Leuven, Belgium - CHU Namur
Namur, Belgium
|
|
| 47 |
NCT03481647 |
Recruiting |
Evaluation of an Oral Care Programme for Head and Neck Cancer Patients |
|
- Procedure: Oral care programme
|
Interventional
|
Not Applicable |
- Göteborg University
- Ryhov County Hospital
- FUTURUM, Academy of Health and Science
- Swedish Cancer Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03481647 |
831-16 |
|
January 8, 2018 |
December 31, 2020 |
December 31, 2023 |
March 29, 2018 |
March 29, 2018 |
|
- Institute of odontology
Gothenburg, Sweden - Länssjukhuset Ryhov
Jönköping, Sweden
|
|
| 48 |
NCT03380208 |
Recruiting |
Comparison of Endoscopic Visualization and CT Imaging of Head and Neck Cancers With Pathological Validation Study |
|
|
Observational
|
|
- University Health Network, Toronto
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- CT image comparison of lesions visible in the oral cavity with pathological findings of the resected specimen.
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03380208 |
17-5386 |
EndoscopicHN |
December 1, 2017 |
August 31, 2019 |
August 31, 2019 |
December 21, 2017 |
December 21, 2017 |
|
- University Health Network
Toronto, Ontario, Canada
|
|
| 49 |
NCT03081897 |
Recruiting |
Regional Anaesthesia and Substance P in Head and Neck Cancer |
|
- Drug: SPRANC Block group
- Drug: SPRANC Control group
|
Interventional
|
Not Applicable |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Expression of Substance P
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03081897 |
EA1/119/16 |
SPRANC |
July 2016 |
July 2018 |
July 2019 |
March 16, 2017 |
June 6, 2017 |
|
- Charité Universitaetsmedizin Berlin
Berlin, Germany
|
|
| 50 |
NCT03539198 |
Recruiting
New |
Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer |
|
- Radiation: Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)
- Radiation: Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).
- Drug: Nivolumab 3 mg/kg IV q2 weeks
- Radiation: Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Objective response rate (ORR) using iRECIST 1.1 criteria for locoregional arm
- Objective response rate (ORR) using iRECIST 1.1 criteria for metastatic arm
- Local control rate for both arms
- (and 8 more...)
|
91 |
All |
18 Years and older (Adult, Older Adult) |
NCT03539198 |
17-010910
ROR1771 |
|
June 2018 |
May 2022 |
June 2022 |
May 28, 2018 |
June 4, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
Create an RSS feed from your search for:
Download the search results for: